alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
i i i i i i



### MEM ORA ND UM OP INION No
. 04 -0 9- 00 27 1- CR Jesu s ES PINO ZA , Appellant
v . The STA TE of Texas, Appellee Fr om the 144th J udicial District Court, Be x ar County , Texas

Trial Court No. 2007-CR-9689 Honora ble Catherine Torre s-Stahl, J udg e Presiding

PER C URI AM Sitt ing: Sandee B ry an Mar ion , J ustice

Phy lis J . Speedlin, J ustice Rebec ca Simmons, J ustice Deliver ed and F iled: J une 10, 2009 DI SMI SSED The trial c ourt signe d a ce rtification of de fenda nt’s rig ht to appeal stating that this “is a pleabarg ain ca se, and the defe ndant has NO rig ht of appea l” and that “def endant has wa ived the rig ht of appea l.” See T EX . R. A PP . P. 25 .2 (a )( 2)
. Rul e 25 .2 (d ) pr ov ide s, “ Th e a pp e a l mu st b e dis mis se d if04
- 09
- 00 27 1- CR

- 2- a certifica tion that shows the defendant has the right of appeal has not been made part of the re cord under the se rules.” T EX . R. A PP . P. 25.2(d). Acc ording ly , on May 28, 2009, thi s court issued a n order stating this appe al would be dismissed pursuant to Rule 25.2(d) unless an amended trial court
cer tification that shows defe ndant has the right of appe al was ma de par t of the appe llate re cord. See Da nie ls v . S

tat e ,1 10 S.W. 3d

17 4 ( Te x. Ap p. —Sa

n A nto nio 20 03 , o rd e r) ; T EX . R. A PP . P. 25.2(d); 37.1. On May

29, 2009, defe ndant’s appe llate counsel filed a letter stating “this court has no choice but to dism iss the appea l.” I n light of the record presented, we agr ee with defe ndant’s counsel that Rule 25.2(d) re quires this court to dismiss t his appea l. Accor dingly , this appeal is dismissed. PER C URI AM

DO NO T PU B L I SH
N

emo

Piedmont

Meade

Pennington

Lawrence

Pennington

Meade

Lawrence

T03NR05E

T03NR06E

T02NR06E

T02NR05E

T03NR07E

T02NR07E

T04NR05E

T04NR06E

T03NR04E

T02NR04E

T04NR04E

1

76

2

8

8

4

8

3

1

2

9

4

5

4

5

5

3

5

7

7

1

8

2

3

9

8

9

6

5

4

9

76

8

6

6

7

7

11

12

11

11

11

183

1

1930

9

31

36

34

32

24

33

25

12

16

26

12

10

36

13

34

14

23

33

32

21

35

17

28

27

12

14

23

32

24

13

102227

29

25

31

16

22

15

19

2029

20

17

10

26

10

21

30

15

35

29

31

18

30

28

19

18

20

17

32

33

34

35

36

31

32

4

33

9

1

13

18

17

14

15

1

13

16

16

17

21

18

28

14

15

33

18

17

16

12

36

25

24

13

12

36

16

.130

0.5123

Miles

SteamboatProposedAction

SteamboatBoundary

PrivateLand

ProposedTransportationSystem

Existing

NewConstruction

NewConversion

Reconstruction/Pre-useMaintenance

Decommission

ProposedVegetationTreatments

CommercialHardwoodEnhancement

HardwoodEnhancement

CommercialMeadowEnhancement

MeadowEnhancement

CommercialThin-40BA

CommercialThin-50BA

CommercialThin-60BA

CommercialThin-80BA

GroupSelection

IndividualTreeSelection

OverstoryRemoval

PatchClearcut

Non-commercialThin

Product-other-than-log

ShelterwoodCut

UnderstoryThin

PrescribedFire
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.1270 Intracavitary phonocatheter system. ( a ) *Identification.* An intracavitary phonocatheter system is a system that includes a catheter with an acoustic transducer and the associated device that processes the signal from the transducer; this device records bioacoustic phenomena from a transducer placed within the heart, blood vessels, or body cavities.
( b ) *Classification.* Class II (performance standards).
# C_2014380EN.01001501.xml

| 27.10.2014 | EN | Official Journal of the European Union | C 380/15 |
| --- | --- | --- | --- |

27.10.2014

EN

Official Journal of the European Union

C 380/15

---

Action brought on 28 July 2014 — Ahmed Mohamed Saleh Baeshen v OHIM

(Case T-564/14)

2014/C 380/20

Language of the case: English

Parties

Parties

Applicant: Ahmed Mohamed Saleh Baeshen & Co. (Jeddah, Saudi Arabia) (represented by: M. Vanhegan, Barrister)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 19 May 2014 given in Case R 687/2014-2; |
| --- | --- |

—

Annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 19 May 2014 given in Case R 687/2014-2;

| — | Order the defendant to bear the costs of proceedings. |
| --- | --- |

—

Order the defendant to bear the costs of proceedings.

Pleas in law and main arguments

Pleas in law and main arguments

Registered Community trade mark in respect of which an application for revocation has been made: The word mark ‘TEAVANA’ for services in Class 35 — Community trade mark No 4 0 98  588

Registered Community trade mark in respect of which an application for revocation has been made:

Proprietor of the Community trade mark: The other party to the proceedings before the Board of Appeal, Teavana Corporation

Proprietor of the Community trade mark:

Party applying for revocation of the Community trade mark: The applicant

Party applying for revocation of the Community trade mark:

Decision of the Cancellation Division: Revoked the CTM proprietor’s right in respect of Community trade mark No 4 0 98  588 in its entirety

Decision of the Cancellation Division:

Decision of the Board of Appeal: Rejected the appeal as inadmissible

Decision of the Board of Appeal:

Pleas in law: Infringement of Articles 51(1)(a), 59 and 75 CTMR.

Pleas in law:

---
[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Pages 10331-10332]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4801]


-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[File No. 500-1]


In the Matter of: Amalgamated Explorations, Inc., Areawide 
Cellular, Inc., Genomed, Inc., Global Maintech Corp., Military Resale 
Group, Inc., Verado Holdings, Inc., and World Transport Authority, 
Inc.; Order of Suspension of Trading

    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
Amalgamated Explorations, Inc. because it has not filed any periodic 
reports since the period ended March 31, 2000.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
Areawide Cellular, Inc. because it has not filed any periodic reports 
since the period ended September 30, 2002.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
Genomed, Inc. because it has not filed any periodic reports since the 
period ended March 31, 2005.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
Global Maintech Corp. because it has not filed any periodic reports 
since the period ended December 31, 2002.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
Military Resale Group, Inc. because it has not filed any periodic 
reports since the period ended September 30, 2004.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
Verado Holdings, Inc. because it has not filed any periodic reports 
since the period ended September 30, 2001.
    It appears to the Securities and Exchange Commission that there is 
a lack of current and accurate information concerning the securities of 
World Transport Authority, Inc. because it has not filed any periodic 
reports since the period ended March 31, 2004.
    The Commission is of the opinion that the public interest and the 
protection of investors require a suspension of trading in the 
securities of the above-listed companies. Therefore, it is ordered, 
pursuant to Section 12(k) of the Securities Exchange Act of 1934, that 
trading in the securities of the above-

[[Page 10332]]

listed companies is suspended for the period from 9:30 a.m. EST on 
March 3, 2010, through 11:59 p.m. EDT on March 16, 2010.

    By the Commission.
Elizabeth M. Murphy,
Secretary.
[FR Doc. 2010-4801 Filed 3-3-10; 4:15 pm]
BILLING CODE 8011-01-P
<PAGE>
                                                                   EXHIBIT 10.6

                                SECOND AMENDMENT
                                     TO THE
                                  ZONAGEN, INC.
                 2000 NON-EMPLOYEE DIRECTORS' STOCK OPTION PLAN

         This Second Amendment to the Zonagen, Inc. (the "Company") 2000
Non-Employee Directors' Stock Option Plan, as amended, (the "Amendment") is
executed pursuant to Section 12 of the Company's 2000 Non-Employee Directors'
Stock Option Plan (the "Plan"). All capitalized and undefined terms used herein
shall have the meanings ascribed to such terms in the Plan.

         WHEREAS, the Company's Board of Directors (the "Board") is authorized
by Section 12 of the Plan to amend the Plan from time to time, subject to any
required stockholder approval of any such amendments; and

         WHEREAS, the Board desires to amend the Plan, effective as of June 27,
2002, to allow for issuance of stock awards and options under the Plan in order
to allow the Company to pay fees for certain meetings owed to directors in stock
awards and options in lieu of cash; and

         WHEREAS, such amendments do not require stockholder approval as set
forth in Section 12 of the Plan.

         NOW, THEREFORE, in connection with the foregoing, the Plan is hereby
amended as follows:

         1. Section 7(a) of the Plan up to but not including subsections (i) and
(ii) thereunder, which subsections shall remain, is hereby deleted in its
entirety and replaced with the following:

                  "(a) PER-MEETING FEE. The Company shall pay each Non-Employee
                  Director One Thousand Dollars ($1,000) (the "Director Fee") in
                  (x) cash, (y) shares of Common Stock; or (z) an Option (the
                  "Director Fee Option") to purchase shares of Common Stock, at
                  his or her election, for each meeting of the Board or any
                  committee of the Board at which he or she attends in person or
                  telephonically. If a Non-Employee Director elects to receive
                  Common Stock or an Option, the number of shares to be granted
                  pursuant to this Section 7(a) shall be determined in
                  accordance with the following:"

         2. Except as amended hereby, the terms and provisions of the Plan shall
remain in full force and effect, and the Plan and this Amendment shall be read,
taken and construed as one and the same instrument.

         IN WITNESS WHEREOF, and as conclusive evidence of the adoption and
approval of the foregoing Second Amendment to the Plan by the Board, the Company
has caused this Amendment to be duly executed in its name and behalf by its
proper officers thereunto duly authorized as of the 24th day of October, 2002.


                                     ZONAGEN, INC.


                                     By:  /s/ Joseph S. Podolski
                                          -------------------------------------
                                          Joseph S. Podolski,
                                          President and Chief Executive Officer
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.2330 Enriched culture medium. ( a ) *Identification.* An enriched culture medium is a device that consists primarily of liquid or solid biological materials intended for medical purposes to cultivate and identify fastidious microorganisms (those having complex nutritional requirements). The device consists of a relatively simple basal medium enriched by the addition of such nutritional components as blood, blood serum, vitamins, and extracts of plant or animal tissues. The device is used in the diagnosis of disease caused by pathogenic microorganisms and also provides epidemiological information on these diseases.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 54 FR 25046, June 12, 1989; 66 FR 38791, July 25, 2001]
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.9160 Blood group substances of nonhuman origin for in vitro diagnostic use. ( a ) *Identification.* Blood group substances of nonhuman origin for in vitro diagnostic use are materials, such as blood group specific substances prepared from nonhuman sources (e.g., pigs, cows, and horses) used to detect, identify, or neutralize antibodies to various human blood group antigens. This generic type of device does not include materials that are licensed by the Center for Biologics Evaluation and Research of the Food and Drug Administration.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 864.9.
[45 FR 60640, Sept. 12, 1980, as amended at 53 FR 11253, Apr. 6, 1988; 63 FR 59225, Nov. 3, 1998]
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.1470 Computerized cognitive assessment aid. ( a ) *Identification.* The computerized cognitive assessment aid is a prescription device that uses an individual's score(s) on a battery of cognitive tasks to provide an interpretation of the current level of cognitive function. The computerized cognitive assessment aid is used only as an assessment aid to determine level of cognitive functioning for which there exists other valid methods of cognitive assessment and does not identify the presence or absence of clinical diagnoses. The computerized cognitive assessment aid is not intended as a stand-alone or adjunctive diagnostic device.
( b ) *Classification.* Class II (special controls). Except when the computerized cognitive assessment aid is intended for diagnostic assessment of specific diseases or conditions and relies on inputs from visual cues, auditory cues, and/or functional use of the hand, the device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 882.9. The special control(s) for this device are: ( 1 ) The technical parameters of the device's hardware and software must be fully characterized and be accompanied by appropriate non-clinical testing: ( i ) Hardware specifications must be provided. Appropriate verification, validation, and hazard analysis must be performed.
( ii ) Software, including any proprietary algorithm(s) used by the device to arrive at its interpretation of the patient's cognitive function, must be described in detail in the software requirements specification (SRS) and software design specification (SDS). Appropriate software verification, validation, and hazard analysis must be performed.
( 2 ) The device must be designed and tested for electrical safety.
( 3 ) The labeling must include: ( i ) A summary of any testing conducted to demonstrate how the device functions as an interpretation of the current level of cognitive function. The summary of testing must include the following, if available: Any expected or observed adverse events and complications; any performance measurements including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) per the devices intended use; a description of the repeatability of measurements; a description of how the cut-off values for categorization of measurements were determined; and a description of the construct validity of the device.
( ii ) A warning that the device does not identify the presence or absence of clinical diagnoses.
( iii ) A warning that the device is not a stand-alone diagnostic.
( iv ) The intended use population and the intended use environment.
( v ) Any instructions technicians must convey to patients regarding the administration of the test and collection of cognitive test data.
[80 FR 49138, Aug. 17, 2015, as amended at 84 FR 71815, Dec. 30, 2019]
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1650 Ophthalmic bar prism. ( a ) *Identification.* An ophthalmic bar prism is a device that is a bar composed of fused prisms of gradually increasing strengths intended to measure latent and manifest strabismus (eye muscle deviation) or the power of fusion of a patient's eyes.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[52 FR 33355, Sept. 2, 1987, as amended at 53 FR 35605, Sept. 14, 1988; 66 FR 38812, July 25, 2001]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5350 Fibrinopeptide A immunological test system. ( a ) *Identification.* A fibrinopeptide A immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the fibrinopeptide A (a blood-clotting factor) in plasma and other body fluids. Measurement of fibrinopeptide A may aid in the diagnosis and treatment of certain blood-clotting disorders.
( b ) *Classification.* Class II (performance standards).
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7903 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7903

To amend the Internal Revenue Code of 1986 to allow elective payment of 
  applicable credits to bona fide residents of and entities organized 
                     under the laws of Puerto Rico.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 9, 2024

Mrs. Gonzalez-Colon (for herself, Mr. Torres of New York, and Mr. Soto) 
 introduced the following bill; which was referred to the Committee on 
                             Ways and Means

_______________________________________________________________________

                                 A BILL

 
To amend the Internal Revenue Code of 1986 to allow elective payment of 
  applicable credits to bona fide residents of and entities organized 
                     under the laws of Puerto Rico.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. AVAILABILITY OF ELECTIVE PAYMENT OF APPLICABLE CREDITS TO 
              PUERTO RICAN RESIDENTS AND ENTITIES.

    (a) In General.--Section 6417(d)(1)(A) of the Internal Revenue Code 
of 1986 is amended by striking ``or'' and the end of clause (v), by 
striking the period at the end of clause (vi) and inserting ``, or'', 
and by adding at the end the following new clause:
                            ``(vii) a public entity, nonprofit 
                        organization, or electric cooperative organized 
                        under the laws of Puerto Rico.''.
    (b) Exception From Requirement That Property Is Located in the 
United States.--Section 6417(d)(2) of such Code is amended by striking 
``and'' at the end of subparagraph (A), by striking the period at the 
end of subparagraph (B) and inserting ``, and'', and by adding at the 
end the following new subparagraph:
                    ``(C) in the case of property which is used 
                predominately in a United States possession, without 
                regard to sections 50(b)(1) and 30C(e)(3).''.
    (c) Effective Date.--The amendments made by this section shall 
apply to facilities and property placed in service after the date of 
the enactment of this section.
                                 <all>
```
Editorial Note on Part 892
Editorial Note: Nomenclature changes to part 892 appear at 73 FR 35341, June 23, 2008.

§ 892.1610 Diagnostic x-ray beam-limiting device. ( a ) *Identification.* A diagnostic x-ray beam-limiting device is a device such as a collimator, a cone, or an aperture intended to restrict the dimensions of a diagnostic x-ray field by limiting the size of the primary x-ray beam.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
[48 FR 53047, Nov. 23, 1983, as amended at 84 FR 71818, Dec. 30, 2019]
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.6050 Ice bag. ( a ) *Identification.* An ice bag is a device intended for medical purposes that is in the form of a container intended to be filled with ice that is used to apply dry cold therapy to an area of the body. The device may include a holder that keeps the bag in place against an external area of the patient.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 880.9. If the device is not labeled or otherwise represented as sterile, it is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
[45 FR 69682, Oct. 21, 1980, as amended at 66 FR 38805, July 25, 2001]
§ 876.5970 Hernia support. ( a ) *Identification.* A hernia support is a device, usually made of elastic, canvas, leather, or metal, that is intended to be placed over a hernial opening (a weakness in the abdominal wall) to prevent protrusion of the abdominal contents. This generic type of device includes the umbilical truss.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, regarding general requirements concerning records, and § 820.198, regarding complaint files.
[48 FR 53023, Nov. 23, 1983, as amended at 59 FR 63010, Dec. 7, 1994; 66 FR 38802, July 25, 2001]